- In April 2024, Pfizer Inc. announced the launch of its next-generation hormone replacement therapy (HRT) for managing postmenopausal symptoms and osteoporosis associated with estrogen deficiency. The therapy integrates a novel delivery system to enhance hormone absorption and patient compliance, underscoring Pfizer’s commitment to advancing treatment options in the endocrine disorders landscape
- In March 2024, Eli Lilly and Company received FDA approval for its new long-acting GLP-1 receptor agonist aimed at improving glycemic control in patients with Type 2 diabetes. This milestone expands the company’s endocrinology portfolio and emphasizes its strategic focus on metabolic and endocrine health innovations
- In February 2024, Novartis AG announced positive Phase III trial results for its investigational therapy targeting acromegaly, a rare endocrine disorder. The new formulation demonstrated improved efficacy and safety over existing treatments, positioning Novartis to meet the growing demand for targeted endocrine therapeutics
- In January 2024, Abbott Laboratories introduced an upgraded version of its continuous glucose monitoring (CGM) system tailored for pediatric patients with diabetes. The launch addresses an underserved population within the endocrine disorders market and highlights Abbott's efforts in advancing pediatric endocrinology care through wearable technologies
- In December 2023, Sanofi entered into a strategic collaboration with a leading biotech firm to co-develop innovative gene therapies for congenital endocrine disorders such as congenital adrenal hyperplasia. This partnership reflects Sanofi’s ambition to explore curative approaches and expand its footprint in the rare endocrine disease segment
